Overview
Overproduction of growth hormone (GH), often referred to as acromegaly when caused by a pituitary adenoma, is characterized by excessive GH secretion leading to elevated levels of insulin-like growth factor 1 (IGF-1). This condition primarily affects adults, typically middle-aged individuals, and can result from benign pituitary tumors or, less commonly, ectopic sources of GH-releasing hormone or GH itself. Clinically significant due to its impact on bone metabolism, cardiovascular health, and quality of life, overproduction of GH necessitates early detection and management to mitigate long-term complications. Understanding and addressing this condition is crucial in day-to-day practice to prevent irreversible organ damage and improve patient outcomes 1234.Pathophysiology
The overproduction of growth hormone (GH) primarily stems from a pituitary adenoma, which secretes GH autonomously, bypassing normal hypothalamic regulation. At the molecular level, this unregulated GH secretion leads to elevated levels of IGF-1, which mediate many of the clinical manifestations observed in acromegaly. GH exerts its effects through binding to its receptor on target tissues, activating downstream signaling pathways such as the JAK-STAT pathway and the MAPK pathway, promoting cell proliferation and differentiation. These pathways are particularly active in bone, cartilage, and soft tissues, leading to characteristic features like acral enlargement, joint pain, and organomegaly. Additionally, chronic GH excess can disrupt normal endocrine functions, affecting glucose metabolism and potentially leading to insulin resistance and diabetes mellitus 234.Epidemiology
The incidence of acromegaly, primarily due to GH overproduction, is estimated to be around 40 to 70 new cases per million people annually. It predominantly affects adults, with a median age at diagnosis of approximately 40 years, and shows no significant gender predilection. Geographic variations exist, but no clear trends indicate a rising or falling incidence globally. Risk factors include genetic predispositions and certain environmental exposures, though specific risk factors remain incompletely defined. Early diagnosis is challenging due to the gradual onset of symptoms, often leading to delayed treatment initiation 23.Clinical Presentation
Patients with overproduction of growth hormone typically present with a constellation of symptoms including gradual enlargement of hands and feet, coarse facial features, deepening of the voice, joint pain, and excessive sweating. Other common manifestations include carpal tunnel syndrome, headaches, visual disturbances (due to pituitary tumor compression), and skin changes such as thickening and oily skin. Red-flag features include severe hypertension, cardiac hypertrophy, and impaired glucose tolerance, which necessitate urgent evaluation and management. Atypical presentations can occur, particularly in pediatric cases or when GH excess is due to ectopic sources, highlighting the importance of thorough clinical assessment 234.Diagnosis
Diagnosing overproduction of growth hormone involves a multi-step approach focusing on biochemical markers and imaging studies. Initial screening typically includes measuring serum IGF-1 levels, which are typically elevated in acromegaly. If IGF-1 levels are abnormal, confirmatory testing with a GH suppression test (often using oral glucose tolerance test) is performed to assess GH pulsatility. A GH level above 1 μg/L during the OGTT confirms GH excess. Imaging studies, particularly MRI of the pituitary gland, are crucial for identifying pituitary adenomas or other sources of GH overproduction. Specific criteria include:Differential Diagnosis
Management
First-Line Treatment
Second-Line Treatment
Refractory or Specialist Escalation
Contraindications
Complications
Prognosis & Follow-Up
The prognosis for patients with overproduction of growth hormone significantly improves with early and effective treatment. Key prognostic indicators include the extent of tumor resection, normalization of IGF-1 levels, and control of comorbidities. Recommended follow-up intervals include:Special Populations
Key Recommendations
References
1 Li CH, Yamashiro D, Tseng LF, Chang WC, Ferrara P. beta-Endorphin: synthesis of analogs modified at the carboxyl terminus with increased activites. Proceedings of the National Academy of Sciences of the United States of America 1979. link 2 Johansson J, Grönbladh A, Nyberg F, Hallberg M. Application of in vitro [³⁵S]GTPγ-S autoradiography in studies of growth hormone effects on opioid receptors in the male rat brain. Brain research bulletin 2013. link 3 Coleman ES, Sartin JL. Endotoxin stimulates in vitro pituitary growth hormone release in eicosanoid-dependent manner. American journal of veterinary research 1996. link 4 Di Simone N, Caruso A, Lanzone A, Piccirillo G, Castellani R, Ronsisvalle E et al.. In vitro human growth hormone increases human chorionic gonadotropin and progesterone secretion by human placenta at term: evidence of a modulatory role by opioids. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1995. link 5 Cronin MJ, MacLeod RM, Canonico PL. Modification of basal and GRF-stimulated cyclic AMP levels and growth hormone release by phospholipid metabolic enzyme inhibitors. Neuroendocrinology 1985. link